Alnylam Pharmaceuticals Non-GAAP EPS of $16.26 beats by $14.01, revenue of $1.46B beats by $30M (ALNY:NASDAQ)
· seekingalpha.com
Alnylam Pharmaceuticals Q3 earnings surged on strong revenue and a major EPS beat.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...